Highlights

Good Articles to Share

Author: Tan KW   |   Latest post: Tue, 24 Nov 2020, 10:34 PM

 

Mexico will not follow FDA in approving Gilead's COVID-19 drug

Author:   |    Publish date:


MEXICO CITY - Mexico will not necessarily follow the U.S. Food and Drug Administration (FDA) in approving Gilead Science Inc's antiviral drug remdesivir for use in COVID-19 patients, a top Mexican health official said on Friday.

Mexico's health regulator Cofepris has already twice denied approval for the drug with a "non-favorable" opinion, deputy health minister Hugo Lopez-Gatell told his regular nightly news conference.

"We have no mandate from the FDA," he said. "Cofepris has identified that the evidence does not suggest a usefulness, a sufficient efficacy."

The FDA approved remdesivir on Thursday, making it the first and only drug approved for the disease in the United States.

Remdesivir, given intravenously, was one of the drugs used to treat U.S. President Donald Trump during his bout with COVID-19.

The World Health Organization's (WHO) Solidarity drug trial last week concluded remdesivir has little or no impact on a patient's chances of surviving COVID-19, and a top WHO scientist on Friday recommended the FDA consider all available evidence.

Lopez-Gatell said Gilead had sent a letter to doctors in Mexico refuting the results of the Solidarity trial, and that officials were looking to see if the letter could be cause for sanction, given that remdesivir is not registered with Mexican health authorities.

"It confuses the population and generates a false expectation of the possibility of having a treatment option," he said.

Gilead did not immediately respond to a request for comment.

 


  - Reuters

 

Share this

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
Perform Technical & Fundamental Analysis on Stocks
MQ Affiliate
Earn rewards by referring your friends
 
 

241  924  499  511 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 AT 0.155-0.015 
 PHB 0.030.00 
 SAPNRG 0.115-0.005 
 VIVOCOM 0.855-0.365 
 KANGER 0.18-0.015 
 PA 0.145-0.005 
 MTRONIC 0.105-0.01 
 KGROUP-WC 0.020.00 
 XDL 0.07-0.005 
 ARMADA 0.27-0.005 

FEATURED POSTS

1. The Equity Market Index Benchmark in Malaysia CMS
2. Trading Scenarios of Derivatives Bursa Derivatives Education Series
3. Derivatives 101 Bursa Derivatives Education Series
4. Why Trade FKLI? Bursa Derivatives Education Series
5. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!
PARTNERS & BROKERS